MP29-02: a breakthrough for the treatment of allergic rhinitis

Bibliography

• Canonica GW, Bousquet J, Mullol J, et al. A survey of the burden of allergic rhinitis in Europe. Allergy 2007;62(Suppl 85):17-25
   PubMed Web of Science ®Google Scholar
• Schatz M. A survey of the burden of allergic rhinitis in the USA. Allergy 2007;62(Suppl 85):9-16
   PubMed Web of Science ®Google Scholar
• Bernstein JA, Levin LS, Al-Shuik E, et al. Clinical characteristics of chronic rhinitis patients with high vs low irritant trigger burdens. Ann Allergy Asthma Immunol 2012;109:173-8
   Google Scholar
• Bernstein JA. Allergic and mixed rhinitis: epidemiology and natural history. Allergy Asthma Proc 2010;31:365-9
   PubMed Web of Science ®Google Scholar
• Mosges R, Klimek L. Today's allergic rhinitis patients are different: new factors that may play a role. Allergy 2007;62:969-75
   PubMed Web of Science ®Google Scholar
• Bousquet J, Bachert C, Canonica GW, et al. Extended Global Allergy and Asthma European Network, World Allergy Organization and Allergic Rhinitis and its Impact on Asthma Study Group. Unmet needs in severe chronic upper airway disease (SCUAD). J Allergy Clin Immunol 2009;124:428-33
   PubMed Web of Science ®Google Scholar
• Bousquet PJ, Bachert C, Canonica GW, et al. Uncontrolled allergic rhinitis during treatment and its impact on quality of life: a cluster randomized trial. J Allergy Clin Immunol 2010;126:666-8
   PubMed Web of Science ®Google Scholar
• Hellings PW, Fokkens WJ, Akdis C, et al. Uncontrolled allergic rhinitis and chronic rhinosinusitis: where do we stand today? Allergy 2013;68:1-7
   PubMed Web of Science ®Google Scholar
• Bousquet J, Khaltaev N, Cruz AA, et al. Allergic rhinitis and its Impact on Asthma (ARIA) 2008 update (In collaboration with the World Health Organization, GA(2)LEN and AllerGen. Allergy 2008;63(Suppl 86):8-160
   PubMed Web of Science ®Google Scholar
• Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Global Allergy and Asthma European Network; Grading of Recommendations Assessment, Development and Evaluation Working Group. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010;126:466-76
   PubMed Web of Science ®Google Scholar
• Wallace DV, Dykewicz MS, Bernstein DI, et al. Joint Tast Force on Practice; American Academy of Allergy Asthma & Immunology; American College of Allergy Asthma & Immunology; Joint Council of Allergy Asthma & Immunol. The diagnosis and management of rhinitis; an updated practice parameter. J Allergy Clin Immunol 2008;122(2 Suppl):S1-84
   PubMed Web of Science ®Google Scholar
• Bousquet PJ, Demoly P, Devillier P, et al. Impact of allergic rhinitis symptoms on quality of life in primary care. Int Arch Allergy Immunol 2013;160:393-400
   PubMed Web of Science ®Google Scholar
• Pitman R, Paracha N, Parker C, et al. Episode pattern and healthcare utilisation in patients with seasonal allergic rhinitis. Presented at EAACI; 16–20 June 2012; Geneva
   Google Scholar
• Demoly P, Allaert FA, Lecasble M. PrAGMA. ERASM, a pharmacoepidemiologic survey on management of intermittent allergic rhinitis in every day general medical practice in France. Allergy 2002;57:546-54
   Google Scholar
• Dalal AA, Standrod R, Henry H, et al. Economic burden of rhinitis in managed care: a retrospective claims data analysis. Ann Allergy Asthma Immunol 2008;101:23-9
   PubMed Web of Science ®Google Scholar
• Mullol J. A survey of the burden of allergic rhinitis in Spain. J Investig Allergol Clin Immunol 2009;19:27-34
   PubMed Web of Science ®Google Scholar
• Price D, Bousquet J, Pitman R, et al. Sub-optimal control of allergic rhinitis: the need for a new and more effective treatment option. Presented at EAACI; 22–26 June 2013; Milan
   Google Scholar
• Nathan RA. The burden of allergic rhinitis. Allergy Asthma Proc 2007;28(1):3-9
   PubMed Web of Science ®Google Scholar
• Meltzer EO, Gross GN, Katial R, et al. Allergic rhinitis substantially impacts patient quality of life: findings from the Nasal Allergy Survey Assessing Limitations. J Fam Pract 2012;61(2 Suppl):S5-10
   Google Scholar
• Meltzer E, Ratner P, Bachert C, et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol 2013;161(4):369-77
   PubMed Web of Science ®Google Scholar
• Derendorf H, Munzel U, Petzold U, et al. Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray. Br J Clin Pharmacol 2012;74:125-33
   PubMed Web of Science ®Google Scholar
• EMA guideline: guideline on the Clinical Development of Medicinal Products for the Treatment of Allergic Rhinoconjunctivitis. CHMP/EWP/2455/02. 2004. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003554.pdf [Accessed 29 April 2013]
   Google Scholar
• FDA Draft Guidance or Industry Patient-Reported Outcome Measures: use in Medical Product Development to Support Labeling Claims. 2009. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf [Accessed 29 April 2013]
   Google Scholar
• Hampel FC, Ratner PH, Van bavel J, et al. Double-blind placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. Ann Allergy Asthma Immunol 2010;105:168-73
   PubMed Web of Science ®Google Scholar
• Carr W, Bernstein J, Lieberman P, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol 2012;129:1282-9
   PubMed Web of Science ®Google Scholar
• Meltzer EO, LaForce C, Ratner P, et al. MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety. Allergy Asthma Proc 2012;33:324-32
   PubMed Web of Science ®Google Scholar
• Price D, Bousquet J, Hellings P, et al. Short- and long-term safety of MP29-02: a new therapy for the treatment of allergic rhinitis. Presented at SERIN; 21–23March 2013; Leuven
   Google Scholar
• Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 1991;21:77-83
   PubMed Web of Science ®Google Scholar
• International Committee on Harmonization Harmonized Tripartite Guidelines on Good Clinical Practice. 1996. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6_R1/Step4/E6_R1__Guideline.pdf [Accessed 17 June 2011]
   Google Scholar
• Price D, Shah S, Hatia S, et al. A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis. J Investig Allergol Clin Immunol 2013; In press
   Google Scholar
• Meltzer EO, Orgel HA, Bronsky EH, et al. A dose-ranging study of fluticasone propionate aqueous nasal spray for seasonal allergic rhinitis assessed by symptoms rhinomanometry, and nasal cytology. J Allergy Clin Immunol 1990;86:221-30
   PubMed Web of Science ®Google Scholar
• Van As A, Bronsky E, Grossman J, et al. Dose tolerance study of fluticasone propionate aqueous nasal spray in patients with seasonal allergic rhinitis. Ann Allergy 1991;67:156-62
   PubMedGoogle Scholar
• Nathan RA, Bronsky EA, Fireman P, et al. Once daily fluticasone propionate aqueous nasal spray is an effective treatment for seasonal allergic rhinitis. Ann Allergy 1991;67:332-8
   PubMedGoogle Scholar
• Tomooka LT, Murphy C, Davidson TM. Clinical study and literature review of nasal irrigation. Laryngoscope 2000;110:1189-93
   PubMed Web of Science ®Google Scholar
• Cordray S, Harjo JB, Miner L. Comparison of intranasal hypertonic Dead Sea saline spray and intranasal aqueous triamcinolone spray in seasonal allergic rhinitis. Ear Nose Throat J 2005;84:426-30
   PubMedGoogle Scholar
• Leung DYM, Szefler SJ. The Editor's Choice. MP29-02: a major advancement in the treatment of Allergic rhinitis. J Allergy Clin Immunol 2012;129:1216
   PubMedGoogle Scholar